Another bleeding heart: Perioperative heparin management revisited;Un autre cœur qui saigne: Une réévaluation de l'anticoagulation à l'héparine

Canadian Journal of Anesthesia

Volumn 54, Issue 2, 2007, Pages 97-102

  Harle, Christopher C ^a   Murkin, John M ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; ARGATROBAN; GLYCERYL TRINITRATE; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE SULFATE;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; BINDING AFFINITY; CARDIOPULMONARY BYPASS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; EDITORIAL; EXTRACORPOREAL CIRCULATION; HEPARINIZATION; HUMAN; KIDNEY CLEARANCE; PLASMA HALF LIFE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS;

EID: 33947724423     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03022004     Document Type: Editorial

References (15)

1. Bar-Yosef S, Cozart HB, Phillips-Bute B, Mathew JP, Grocott HP. Preoperative low molecular weight heparin reduces heparin responsiveness during cardiac surgery. Can J Anesth 2007; 54: 107-13.
2. Barrow RT, Parker ET, Krishnaswamy S, Lollar P. Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator. J Biol Chem 1994; 269: 26796-800.
3. Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 2162-9.
4. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl): 188S-203S.
5. Nurmohamed MT, Rosendaal FR, Buller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152-6.
6. White B, Perry D. Acquired antithrombin deficiency in sepsis. Br J Haematol 2001; 112: 26-31.
7. Despotis GJ, Levine V, Joist JH, Joiner-Maier D, Spitznagel E. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Anesth Analg 1997; 85: 498-506.
8. RxMed. Available from URL; http://www.rxmed.com/b.main/b2.pharmaceutical/ b2.prescribe.top.html (accessed November 2006).
9. Despotis GJ, Joist JH, Hague CW Jr, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995; 110: 46-54.
10. Gibbs NM, Yim D, Weightman W, Sheminant M, Rowe R. The effect of excess protamine on thrombelastography in vitro. Anaesth Intensive Care 2006; 34: 579-85.
11. Cosgrove DM 3rd, Heric B, Lytle BW et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992; 54: 1031-6.
12. Hunt BJ, Murkin JM. Heparin resistance after aprotinin (Letter). Lancet 1993; 341: 126.
13. Ganter MT, Monn A, Tavakoli R, et al. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot. Eur J Cardiothorac Surg 2006; 30: 278-84.
14. Smedira NG, Dyke CM, Koster A, et al. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg 2006; 131: 686-92.
15. Koster A, Buz S, Hetzer R, Kuppe H, Breddin K, Harder S. Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: first results from the ARG-E03 trial. J Thorac Cardiovasc Surg 2006; 132: 699-700.